Anders Poulsen

List of Publications by Year in descending order

62 papers	1,913 citations	236925 25 h-index	276875 41 g-index
64 all docs	64 docs citations	64 times ranked	3035 citing authors

#	Article	IF	Citations
1	Discovery of the Macrocycle 11-(2-Pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23 (SB1518), a Potent Janus Kinase 2/Fms-Like Tyrosine Kinase-3 (JAK2/FLT3) Inhibitor for the Treatment of Myelofibrosis and Lymphoma. Journal of Medicinal Chemistry, 2011, 54, 4638-4658.	6.4	163
2	Targeting the Central Pocket in Human Transcription Factor TEAD as a Potential Cancer Therapeutic Strategy. Structure, 2015, 23, 2076-2086.	3.3	146
3	SIRT1 Modulating Compounds from High-Throughput Screening as Anti-Inflammatory and Insulin-Sensitizing Agents. Journal of Biomolecular Screening, 2006, 11, 959-967.	2.6	137
4	Discovery of (2E)-3-{2-Butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl}-N-hydroxyacrylamide (SB939), an Orally Active Histone Deacetylase Inhibitor with a Superior Preclinical Profile. Journal of Medicinal Chemistry, 2011, 54, 4694-4720.	6.4	82
5	Design and Synthesis of Ligand Efficient Dual Inhibitors of Janus Kinase (JAK) and Histone Deacetylase (HDAC) Based on Ruxolitinib and Vorinostat. Journal of Medicinal Chemistry, 2017, 60, 8336-8357.	6.4	82
6	Design and Synthesis of Janus Kinase 2 (JAK2) and Histone Deacetlyase (HDAC) Bispecific Inhibitors Based on Pacritinib and Evidence of Dual Pathway Inhibition in Hematological Cell Lines. Journal of Medicinal Chemistry, 2016, 59, 8233-8262.	6.4	78
7	Discovery of Kinase Spectrum Selective Macrocycle (16E)-14-Methyl-20-oxa-5,7,14,26-tetraazatetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-deca (SB1317/TG02), a Potent Inhibitor of Cyclin Dependent Kinases (CDKs), Janus Kinase 2 (JAK2), and Fms-like Tyrosine Kinase-3 (FLT3) for the Treatment of Cancer. Journal of Medicinal Chemistry, 2012, 55, 169-196.	6.4	77
8	Target Mechanism-Based Whole-Cell Screening Identifies Bortezomib as an Inhibitor of Caseinolytic Protease in Mycobacteria. MBio, 2015, 6, e00253-15.	4.1	69
9	Fragment-Based Ligand Design of Novel Potent Inhibitors of Tankyrases. Journal of Medicinal Chemistry, 2013, 56, 4497-4508.	6.4	59
10	Targeting cancer addiction for SALL4 by shifting its transcriptome with a pharmacologic peptide. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E7119-E7128.	7.1	43
11	Discovery of the Macrocycle (9E)-15-(2-(Pyrrolidin-1-yl)ethoxy)-7,12,25-trioxa-19,21,24-triaza-tetracyclo[18.3.1.1(2,5).1(14,18)]hexacosa-1(24),2,4,9,14(26), (SB1578), a Potent Inhibitor of Janus Kinase 2/Fms-LikeTyrosine Kinase-3 (JAK2/FLT3) for the Treatment of Rheumatoid Arthritis. Journal of Medicinal Chemistry, 2012, 55, 2623-2640.	6.4	41
12	Optimization of Selective Mitogen-Activated Protein Kinase Interacting Kinases 1 and 2 Inhibitors for the Treatment of Blast Crisis Leukemia. Journal of Medicinal Chemistry, 2018, 61, 4348-4369.	6.4	37
13	Discovery and Optimization of a Porcupine Inhibitor. Journal of Medicinal Chemistry, 2015, 58, 5889-5899.	6.4	35
14	Structural and ligand-binding analysis of the YAP-binding domain of transcription factor TEAD4. Biochemical Journal, 2018, 475, 2043-2055.	3.7	35
15	Combining the [2,3] sigmatropic rearrangement and ring-closing metathesis strategies for the synthesis of spirocyclic alkaloids. A short and efficient route to (Â±)-perhydrohistrionicotoxin. Tetrahedron, 1999, 55, 1427-1440.	1.9	33
16	Structure-based design of oxygen-linked macrocyclic kinase inhibitors: discovery of SB1518 and SB1578, potent inhibitors of Janus kinase 2 (JAK2) and Fms-like tyrosine kinase-3 (FLT3). Journal of Computer-Aided Molecular Design, 2012, 26, 437-450.	2.9	33
17	Exploring the binding of peptidic West Nile virus NS2Bâ€“NS3 protease inhibitors by NMR. Antiviral Research, 2013, 97, 137-144.	4.1	33
18	Design and synthesis of potent dual inhibitors of JAK2 and HDAC based on fusing the pharmacophores of XL019 and vorinostat. European Journal of Medicinal Chemistry, 2018, 158, 593-619.	5.5	33

#	Article	IF	Citations
19	Targeting the Bacterial Epitranscriptome for Antibiotic Development: Discovery of Novel tRNA-(N¹G37) Methyltransferase (TrmD) Inhibitors. ACS Infectious Diseases, 2019, 5, 326-335.	3.8	33
20	Structure-based design of nitrogen-linked macrocyclic kinase inhibitors leading to the clinical candidate SB1317/TG02, a potent inhibitor of cyclin dependant kinases (CDKs), Janus kinase 2 (JAK2), and Fms-like tyrosine kinase-3 (FLT3). Journal of Molecular Modeling, 2013, 19, 119-130.	1.8	32
21	Feedback regulation on PTEN/AKT pathway by the ER stress kinase PERK mediated by interaction with the Vault complex. Cellular Signalling, 2015, 27, 436-442.	3.6	31
22	Characterization of the histone methyltransferase PRDM9 using biochemical, biophysical and chemical biology techniques. Biochemical Journal, 2014, 461, 323-334.	3.7	30
23	Drug Design For Flavivirus Proteases: What Are We Missing?. Current Pharmaceutical Design, 2014, 20, 3422-3427.	1.9	30
24	Novel Acetamide Indirectly Targets Mycobacterial Transporter MmpL3 by Proton Motive Force Disruption. Frontiers in Microbiology, 2018, 9, 2960.	3.5	28
25	N-Hydroxy-1,2-disubstituted-1H-benzimidazol-5-yl acrylamides as novel histone deacetylase inhibitors: Design, synthesis, SAR studies, and in vivo antitumor activity. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 1403-1408.	2.2	27
26	Identification of covalent active site inhibitors of dengue virus protease. Drug Design, Development and Therapy, 2015, 9, 6389.	4.3	25
27	Towards Selective Mycobacterial ClpP1P2 Inhibitors with Reduced Activity against the Human Proteasome. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	25
28	Structure and Ligand-Based Design of mTOR and PI3-Kinase Inhibitors Leading to the Clinical Candidates VS-5584 (SB2343) and SB2602. Journal of Chemical Information and Modeling, 2014, 54, 3238-3250.	5.4	24
29	Probing the Binding Mechanism of Mnk Inhibitors by Docking and Molecular Dynamics Simulations. Biochemistry, 2015, 54, 32-46.	2.5	24
30	Fragment-Based Drug Discovery of Potent Protein Kinase C Iota Inhibitors. Journal of Medicinal Chemistry, 2018, 61, 4386-4396.	6.4	23
31	Novel agmatine dipeptide inhibitors against the West Nile virus NS2B/NS3 protease: A P3 and N-cap optimization study. European Journal of Medicinal Chemistry, 2013, 62, 199-205.	5.5	22
32	Pharmacophore Model for Wnt/Porcupine Inhibitors and Its Use in Drug Design. Journal of Chemical Information and Modeling, 2015, 55, 1435-1448.	5.4	21
33	Nutrient content in plant-based protein products intended for food composition databases. Journal of Food Composition and Analysis, 2022, 106, 104332.	3.9	21
34	Discovery of Irreversible Inhibitors Targeting Histone Methyltransferase, SMYD3. ACS Medicinal Chemistry Letters, 2019, 10, 978-984.	2.8	20
35	Scaffold Hopping and Optimization of Maleimide Based Porcupine Inhibitors. Journal of Medicinal Chemistry, 2017, 60, 6678-6692.	6.4	19
36	Hydrocarbon stapled B chain analogues of relaxin-3 retain biological activity. Peptides, 2016, 84, 44-57.	2.4	17

#	Article	IF	Citations
37	Structure-based optimization of morpholino-triazines as PI3K and mTOR inhibitors. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 1009-1013.	2.2	16
38	Structureâ€“Activity Relationship Studies of Mitogen Activated Protein Kinase Interacting Kinase (MNK) 1 and 2 and BCR-ABL1 Inhibitors Targeting Chronic Myeloid Leukemic Cells. Journal of Medicinal Chemistry, 2016, 59, 3063-3078.	6.4	16
39	Antiviral activities of peptide-based covalent inhibitors of the Enterovirus 71 3C protease. Scientific Reports, 2016, 6, 33663.	3.3	15
40	Merging of ruxolitinib and vorinostat leads to highly potent inhibitors of JAK2 and histone deacetylase 6 (HDAC6). Bioorganic and Medicinal Chemistry Letters, 2018, 28, 2636-2640.	2.2	15
41	Intranasal administration of a stapled relaxinâ€3 mimetic has anxiolyticâ€and antidepressantâ€like activity in rats. British Journal of Pharmacology, 2019, 176, 3899-3923.	5.4	15
42	Pharmacophore and receptor models for neurokinin receptors. Journal of Computer-Aided Molecular Design, 2003, 17, 765-783.	2.9	14
43	Synthesis and evaluation of alkenyl indazoles as selective Aurora kinase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 2443-2447.	2.2	14
44	Application of Fragmentâ€Based Drug Discovery against DNA Gyraseâ€…B. ChemPlusChem, 2015, 80, 1250-1254.	2.8	14
45	Structure-based design of Aurora A & B inhibitors. Journal of Computer-Aided Molecular Design, 2008, 22, 897-906.	2.9	13
46	Structure-based design of PDK1 inhibitors. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 305-307.	2.2	11
47	Discovery and characterisation of the automethylation properties of PRDM9. Biochemical Journal, 2017, 474, 971-982.	3.7	11
48	A pharmacophore model for NK2 antagonist comprising compounds from several structurally diverse classes. Journal of Computer-Aided Molecular Design, 2002, 16, 273-286.	2.9	10
49	Peptidomimetic ethyl propenoate covalent inhibitors of the enterovirus 71 3C protease: a P2â€“P4 study. Journal of Enzyme Inhibition and Medicinal Chemistry, 2016, 31, 332-339.	5.2	10
50	Discovery of dual GyrB/ParE inhibitors active against Gram-negative bacteria. European Journal of Medicinal Chemistry, 2018, 157, 610-621.	5.5	10
51	2-Anilino-4-aryl-8H-purine derivatives as inhibitors of PDK1. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 2880-2884.	2.2	9
52	Thieno[3,2-d]pyrimidin-4(3H)-one derivatives as PDK1 inhibitors discovered by fragment-based screening. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 4023-4027.	2.2	8
53	CHAPTER 5. Designed Macrocyclic Kinase Inhibitors. RSC Drug Discovery Series, 2014, , 141-205.	0.3	7
54	Fragment-based Discovery of a Small-Molecule Protein Kinase C-iota Inhibitor Binding Post-kinase Domain Residues. ACS Medicinal Chemistry Letters, 2019, 10, 318-323.	2.8	7

#	Article	IF	Citations
55	Stepwise Evolution of Fragment Hits against MAPK Interacting Kinases 1 and 2. Journal of Medicinal Chemistry, 2020, 63, 621-637.	6.4	7
56	Fragment-based lead discovery of indazole-based compounds as AXL kinase inhibitors. Bioorganic and Medicinal Chemistry, 2021, 49, 116437.	3.0	7
57	Strategic Design of Catalytic Lysineâ€Targeting Reversible Covalent BCRâ€ABL Inhibitors**. Angewandte Chemie, 2021, 133, 17268-17274.	2.0	5
58	Discovery of a Novel Mycobacterial Fâ€ATP Synthase Inhibitor and its Potency in Combination with Diarylquinolines. Angewandte Chemie, 2020, 132, 13397-13406.	2.0	4
59	Substrate-based peptidomimetic inhibitors of the Murray Valley encephalitis virus NS2B/NS3 serine protease: A P1â€“P4 SAR study. European Journal of Medicinal Chemistry, 2013, 68, 72-80.	5.5	3
60	Miniature bovine pancreatic trypsin inhibitors (m-BPTIs) of the West Nile virus NS2B-NS3 protease. Journal of Enzyme Inhibition and Medicinal Chemistry, 2016, 31, 194-200.	5.2	1
61	Dual Specific Inhibitors Of The BCR-ABL and MNK Kinases As Potential Therapeutics For Blast Crisis Chronic Myeloid Leukemia. Blood, 2013, 122, 2702-2702.	1.4	1
62	Smyd2 versus Smyd3: structure-based analysis of small-molecule binding selectivity. Acta Crystallographica Section A: Foundations and Advances, 2018, 74, a470-a470.	0.1	0